Abstract
Testing the efficacy of treatments potentially able to modify the course of multiple sclerosis (MS) is more than an issue, as the natural history of this disease is quite variable from patient to patient and in the same patient from time to time [1]. In about 85% of patients, the disease begins with an acute attack, followed by a partial or complete remission. In few cases (2%–4%), the acute attack is followed by a progressive course, with or without plateaus (the so-called transitional form). Most patients enter a relapsing-remitting course, during which they may accumulate some impairment or disability due to the incomplete recovery from relapses. After 10 years, about 50% of these patients enter the progressive course (secondary progressive MS), with or without superimposed relapses; this figure raises to about 80% after 20 years of disease [2-4]. About 15% of the patients have a progressive course from the onset of the disease, without relapses (primary progressive MS) or with superimposed relapses (progressive relapsing MS) [1].
Keywords
- Multiple Sclerosis
- Expand Disability Status Scale
- Retinal Nerve Fiber Layer
- Optic Neuritis
- Evoke Potential
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46: 907–911
Weinshenker BG (1994) Natural history of multiple sclerosis. Ann Neurol 36: S6–S11
Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103: 281–300
Kurtzke JF, Beebe GW, Nagler B, et al. (1977) Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chronic Dis 30: 819–830
Rudick P, Antel J, Confavreux C, et al. (1996) Clinical outcomes assessment in multiple sclerosis. Ann Neurol 40: 469–479
Sharrack B, Hughes RAC (1996) Clinical scales for multiple sclerosis. J Neurol Sci 135: 1–9
Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis: Frequency, patterns and prediction. Neurology 41: 685–691
Amato MP, Ponziani G, Pracucci G, et al. (1995) Cognitive impairment in early onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 52: 168–172
Rao SM, Leo GJ, Haughton VM, et al. (1989) Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39: 161–166
Filippi M, Miller DH (1996) MRI in the differential diagnosis and monitoring the treatment of multiple sclerosis. Curr Opin Neurol 9: 178–186
Filippi M, Horsfield MA, Tofts PS, et al. (1995) Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 118:1601–1612
Gass A, Barker GJ, Kidd D, et al. (1994) Correlation of magnetization transfer ratio with disability in multiple sclerosis. Ann Neurol 36: 62–67
De Stefano N, Matthews PM, Antel JP, et al. (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38: 901–909
Chiappa KH (1980) Pattern shift visual, brainstem auditory and short latency somatosensory evoked potentials in multiple sclerosis. Neurology 30:110–123
Khosbin S, Hallet M (1981) Multimodality evoked potentials and blink reflex in multiple sclerosis. Neurology 31:138–144
Trojaborg W, Petersen E (1979) Visual and somatosensory evoked potentials in multiple sclerosis. J Neurol Neurosurg Psychiatry 42: 323–330
Comi G, Martinelli V, Medaglini S, et al. (1989) Correlation bertween multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. J Neurol 236: 4–8
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS) Neurology 33:1444–1452
The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI
Noseworthy JH, Vandervoort MK, Wong CJ, et al. (1990) Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 40: 971–975
Sipe JC, Knobler RL, Broheny SL, et al. (1984) A neurological rating scale (NRS) for use in multiple sclerosis. Neurology 34: 1368–1372
Goodkin DE, Hertsgaard D, Seminary J (1988) Upper extremity function in multiple sclerosis: Improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehab 69: 850–854
Coste J, Fermanian J, Venot A (1995) Methodological and statistical problems in the construction of composite measurement scales: A survey of six medical and epidemiological journals. Stat Med 14: 331–345
Surridge D, et al. (1969) An investigation of some psychiatric aspects of multiple sclerosis. Br J Psychiatry 155: 749–764
Peyser JM, Edwards KR, Poser CM, Filskov SB (1980) Cognitive fuction in patients with multiple sclerosis. Arch Neurol 37: 577–579
Bertrando P, Maffei C, Ghezzi A (1983) A study of neuropsychological alterations in multiple sclerosis. Acta Psychiatr Belg 83: 13–21
De Smedt L, Swerts M, Geutjens J, Medaer R (1984) Intellectual impairment in multiple sclerosis. In: Gonsette RF, Delmotte P (eds) Immunological and clinical aspects of multiple sclerosis. MTP Press, Lancaster, pp 342–345
Heaton RH, Nelson LM, Thompson DS, et al. (1985) Neuropsychological findings in relapsing remitting and chronic progressive multiple sclerosis. J Consult Clin Psychol 53:103–110
Lyon-Caen O, Jouvent R, Hauser S, et al. (1986) Cognitive function in recent-onset demyelinating diseases. Arch Neurol 43:1138–1141
Comi G, Filippi M, Martinelli V, et al. (1995) Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 132: 222–227
Rovaris M, Filippi M, Falautano M, et al. (1998) Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 50:1601–1608
Rao SM (1986) Neuropsychology of multiple sclerosis: A critical review. ] Clin Exp Neuropsychol 5: 503–542
Heaton RH, Nelson LM, Thompson DS, et al. (1985) Neuropsychological findings in relapsing remitting and chronic progressive multiple sclerosis. J Consult Clin Psychol 53:103–110
Lyon-Caen O, Jouvent R, Hauser S, et al. (1986) Cognitive function in recent-onset demyelinating diseases. Arch Neurol 43:1138–1141
Comi G, Filippi M, Martinelli V, et al. (1995) Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 132: 222–227
Rovaris M, Filippi M, Falautano M, et al. (1998) Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 50:1601–1608
Rao SM (1986) Neuropsychology of multiple sclerosis: A critical review. J Clin Exp Neuropsychol 5: 503–542
Comi G, Filippi M, Martinelli V, et al. (1993) Brain magnetic resonance imaging correlates of cognitive impairment in mutiple sclerosis. J Neurol Sci 115: S66–S73.
Rao SM (1990) Multiple sclerosis. In: Cummings JL (ed) Subcortical dementia. Oxford University Press, New York, pp 164–180
Mahler ME, Benson DF (1990) Cognitive dysfunction in multiple sclerosis: A subcortical dementia? In: Rao SM (ed) Neurobehavioral aspects of multiple sclerosis. Oxford University Press, New York, pp 88–101
Kujala P, Portin R, Ruutiainen J (1997) The progress of cognitive decline in multiple sclerosis. A controlled 3 year follow-up. Brain 120: 289–297
Staples D, Lincoln NB (1979) Intellectual impairment in multiple sclerosis and its relation to functional abilities. Rheumatol Rehab 18:153–160
Callanan MM, Logsdail SJ, Ron MA, Warrington EK (1989) Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis. Brain 112:361–374
Swirsky-Sacchetti T, Mitchell DR, Seward J, et al. (1992) Neuropsychological and structural brain lesions in multiple sclerosis: A regional analysis. Neurology 42: 1291–1295
Arnett PA, Rao SM, Bernardin L, et al. (1994). Relationship between frontal lobe lesions and Wisconsin card sorting test performance in patients with multiple sclerosis. Neurology 44: 420–425
Foong J, Rozewicz L, Quaghebeur G, et al. (1997) Executive functions in multiple sclerosis. The role of frontal lobe pathology. Brain 120:15–26
Wisnieski HM, Oppenheimer D, McDonald WI (1976) Relation between myelination and function. J Neuropathol Exp Neurol 35: 327 (abstract)
Ghatack NR, Hirano A, Lijtmaer H, et al. (1974) Asymptomatic demyelination plaque in the spinal cord. Arch Neurol 30: 484–486
McDonald WI, Sears TA (1970) The effects of experimental demyelination on conduction in the central nervous system. Brain 93: 583–598
Thorpe W, Barker GJ, Jones SJ, et al. (1995) Magnetization transfer ratios and tranverse magnetization decay curves in optic neuritis: Correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry 59: 487–492
Onofrj M, Bazzano S, Malatesta G, et al. (1990) Pathophysiology of delayed evoked potentials in multiple sclerosis. Funct Neurol 5: 301–319
Ulrich J, Groebke-Lorenz W (1983) The optic nerve in multiple sclerosis. A morphological study with retrospective clinico-pathological correlations. Neuroophthalmology 3:149–159
Quigly HA, Addicks EM (1982) Quantitative studies of retinal nerve fiber layer bundles and bundle defect. Arch Ophthalmol 100: 807–814
Celesia GG (1992) Visual evoked potentials in clinical neurology. In: Aminoff M (ed) Electrodiagnosis in clinical neurology. Churchill-Livingstone, New York, pp 467–489
Ingram DA, Thompson AJ, Swash M (1988) Central motor conduction in multiple sclerosis: Evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry 51: 487–494
Hess CW, Mills KR, Murray NMF, et al. (1987) Magnetic brain stimulation: Central motor conduction studies in multiple sclerosis. Ann Neurol 22: 744–752
Comi G, Filippi M, Martinelli V, et al. (1993) Brainstem magnetic resonance imaging and evoked potentials studies of symptomatic multiple sclerosis patients. Eur Neurol 33: 232–237
Sanders EACM, Arts RJHM (1986) Paresthesias in multiple sclerosis. J Neurol Sci 74: 297–305
Yokota T, Hisose K, Tsukagoshi H, Tanabe H (1991) Somatosensory evoked potentials in patients with selective impairment of position sense versus vibration sense. Acta Neurol Scand 84: 201–206
Laidlaw RW, Hamilton MA, Bricker R (1938) The occurrence of dissociated disturbance of pallesthesia and kinesthesia. Bull Neurol Inst NY 7: 303–320
Van der Kamp W, Maertens de Noorthout A, Thompson PD, et al. (1991) Correlation of phasic muscle strength and corticomotoneuronal conduction time in multiple sclerosis. Ann Neurol 29: 6–12
Berardelli A, Inghilleri M, Cruccu G, et al. (1988) Stimulation of motor tracts in multiple sclerosis. J Neurol Neurosurg Psychiatry 51: 677–683
Miller DH, McDonald WI, Blumhardt LD, et al. (1987) MRI of brain and spinal cord in isolated non-compressive spinal cord syndromes. Ann Neurol 22: 714–723
Youl BD, Turano G, Miller DH, et al. (1991) The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and neurophysiological deficits. Brain 114: 2437–2450
Filippi M, Campi A, Mammi S, et al. (1995) Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 58: 31–37
Martinelli V, Comi G (1995) I1 valore prognostico dei potenziali evocati nella sclerosi multipla. In: Comi G (ed) I potenziali evocati nella sclerosi multipla. Springer, Berlin Heidelberg New York, pp 105–116
Shaw NA, Synek VM (1987) Intersession stability of somatosensory evoked potentials. Electroenceph Clin Neurophysiol 66: 281–285
Andersson T, Persson A (1990) Reproducibility of somatosensory evoked potentials (SEPs) after median nerve stimulation. Electromyogr Clin Neurophysiol 30: 205–211
Aminoff MJ, Davis SL, Panitch HS (1984) Serial evoked potentials studies in patients with definite multiple sclerosis. Arch Neurol 41:1197–1202
Anderson DC, Slater GE, Sherman R, et al. (1987) Evoked potentials to test a treatment of chronic multiple sclerosis. Arch Neurol 44:1232–1236
Sorensen PS, Wanscher B, Szpirt W, et al. (1996) Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: A randomized single-masked cross-over pilot study. Neurology 46:1620–1625
Bednarik J, Kadanka Z (1992) Multimodal sensory and motor evoked potentials in a two years follow-up study of MS patients with relapsing course. Acta Neurol Scand 86: 15–18
Iragui VJ, Wiederholt WC, Romine JS (1986) Serial recording of multimodality evoked potentials in multiple sclerosis: A four years follow-up study. Can J Neurol Sci 13: 320–326
Matthews VB, Small DG (1979) Serial recording of visual and somatosensory evoked potentials in multiple sclerosis. J Neurol Sci 40:11–21
Davis SL, Aminoff MJ, Panitch HS (1985) Clinical correlations of serial somatosensory evoked potentials in multiple sclerosis. Neurology 35: 359–365
Walsh JC, Garrick R, Cameron J, et al. (1982) Evoked potentials changes in clinically definite multiple sclerosis: A two years follow up study. J Neurol Neurosurg Psychiatry 45: 494–500
Ghezzi A, Zaffaroni M, Caputo D, et al. (1986) Evaluation of evoked potentials and lymphocyte subsets as possible markers of multiple sclerosis: One year follow-up of 30 patients. J Neurol Neurosurg Psychiatry 49: 913–919
Nuwer MR, Packwood JW, Myers LW, et al. (1987) Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 37:1754–1761
Andersen T, Siden A (1991) Multimodality evoked potentials and neurological phenomenology in patients with multiple sclerosis and potentially related conditions. Electromyogr Clin Neurophysiol 31:109–117
Smith T, Zeeberg I, Sjo O (1986) Evoked potentials in multiple sclerosis before and after high dose methylprednisolone infusion. Eur Neurol 25: 67–73
Weiner HL, Dawson DM (1980) Plasmapheresis in multiple sclerosis: Preliminary study. Neurology 30:1029–1033
Compston DAS, Milligan NM, Hughes PJ, et al. (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: Laboratory results. J Neurol Neurosurg Psychiatry 50: 517–522
DeWeerd AW (1987) Variability of the central conduction in the course of multiple sclerosis: Serial recording of evoked potentials in the evaluation of therapy. Clin Neurol Neurosurg 89: 9–15
Salle JY, Hugon J, Tabaraud F, et al. (1992) Improvement of motor evoked potentials and clinical course post-steroid therapy in multiple sclerosis. J Neurol Sci 108:184–188
La Mantia L, Riti F, Milanese C, et al. (1994) Serial evoked potentials in multiple sclebouts. Relation to steroid treatment. Ital J Neurol Sci 15: 333–340
Calopa M, Bas J, Mestre M, et al. (1995) T cell subsets in multiple sclerosis: A serial study. Acta Neurol Scand 92: 361–368
Bongioanni P, Fioretti C, Vanacore R, et al. (1996) Lymphocyte subsets in multiple sclerosis. A study with two-colour fluorescence analysis. J Neurol Sci 139: 71–77
Stuber A, Martin R, Stone LA, et al. (1996) Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: A serial analysis. J Neuroimmunol 66: 147–151
Martino G, Filippi M, Martinelli V, et al. (1996) Clinical and radiological correlates of a novel T-lymphocyteγ-interferon-activated Ca2+ influx in patients with relapsing-remitting multiple sclerosis. Neurology 46:1416–1421
Hartung HP, Reiners K, Archelos JJ, et al. (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging. Ann Neurol 38: 186–193
Rieckmann P, Altenhofen B, Riegel A, et al. (1997) Soluble adhesion molecules (sVCAM-I and sICAM-I) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 41: 326–333
Mossner R, Fassbender K, Kuhnen J, et al. (1996) Circulating L-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques. J Neuroimmunol 65: 61–65
Nicoletti F, Patti F, Di Marco R, et al. (1996) Circulating serum levels of IL-lra in patients with relapsing-remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-ß treatment. Cytokine 8: 395–400
Zoukos Y, Kidd D, Woodrofe MN, et al. (1994) Increased expression of high affinity IL-2 receptors and ß-adrenoreceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 117: 307–315
Matusevicius D, Navikas V, Soderstrom M, et al. (1996). Multiple sclerosis: The proinflammatory cytokines lymphotoxin-α and tumor necrosis factor-α are upregulated in cerbrospinal fluid mononuclear cells. J Neuroimmunol 66:15–23
Rieckmann P, Albrecht M, Kitze B, et al. (1995) Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease acitivity. Ann Neurol 37: 82–88
Spuler S, Yousry T, Scheller A, et al. (1996). Multiple sclerosis: Prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 66: 57–64
Rovaris M, Barnes D, Woodrofe N, et al. (1996) Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 243: 536–542
Mokhtarian F, Shi Y, Shirazian D, et al. (1994) Defective production of anti-inflammatory cytokine TGF-ß by T cell lines of patients with active multiple sclerosis. J Immunol 152: 6003–6010
Rollnik JD, Sindern E, Schweppe C, Malin JP (1997) Biologically active TGF-ß1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand 96:101–105
Giovannoni G, Lai M, Kidd D, et al. (1997) Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 120:1–13
Nicoletti F, Patti F, Cocuzza C, et al. (1996) Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 70: 87–90
Trotter JL, Clifford DB, Mclnnis JE, et al. (1989) Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 25:172–178
Sharief MK, Hentges R (1991) Association between tumor necrosis factor-αand disease progression in patients with multiple sclerosis. New Engl J Med 325: 467–472
Whitaker JN, Kachelhofer RD, Bradley EL, et al. (1995) Urinary myelin basic proteinlike material as a correlate of the progression of multiple sclerosis. Ann Neurol 38: 625–632
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Italia
About this paper
Cite this paper
Comi, G., Rovaris, M. (1999). Clinical and Paraclinical Outcomes for Treatment Trials in Multiple Sclerosis. In: Filippi, M., Grossman, R.I., Comi, G. (eds) Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-2153-2_2
Download citation
DOI: https://doi.org/10.1007/978-88-470-2153-2_2
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2180-8
Online ISBN: 978-88-470-2153-2
eBook Packages: Springer Book Archive